New learning discoveries about 50998-17-9

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, vi) [(1R,3R)-3-(3-Chloro-phenylethynyl)-3-(4-methoxy-benzyloxy)-cyclohexyl]-quinoxalin-6-yl- amine: A solution of (1 R,3R)-3-(3-Chloro-phenylethynyl)-3-(4-methoxy-benzyloxy)- cyclohexylamine (34 mg), 6-bromoquinoxaline (23 mg), NaOt-Bu (13 mg), Pd2(dba)3 ‘ CHCI3 (1.9 mg) and BINAP (3.5 mg) in de-gassed toluene (2 ml) was stirred under Ar atmosphere for 1.5 h at 100. The mixture was distributed between cold 1 M Na2CO3 and EtOAc, the phases EPO separated, the aqueous phase ectracted with EtOAc, the combined organic phases dried over Na2SO4 and evaporated. Chromatography afforded 38 mf of the desired product (83%).

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GmbH; WO2006/114260; (2006); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider